EFFECTS OF INJECTIO MEGO-E ON BLOOD GLUCOSE AND SERUM INSULIN LEVELS

Oral glucose tolerance test (OGTT) and serum insulin were studied in 30 healthy young women prior to and during Injectio Mego-E treatment at the 1st, 3rd, 6th and 12th menstrual cycles. The overall results of OGTT at various cycles were within normal limits. Fifteen women developed borderline abnormal glucose tolerance as judged by the Wilkerson score system. However, in all of them except one glucose tolerance became normal spontaneously at the 12th cycle. Serum insulin levels of all the four cycles during treatment were increased not only in the fasting and the 3rd h serum samples but also at 1/2 and 1h samples of the 6th cycle and 1/2 h sample of the 12th cycle. Insulin-glucose index increased in parallel with increase of serum insulin levels. This hyperinsulinemia occurred most probably as a result of drug stimulation following administration of Injectio Mego-E. So far as glucose tolerance, serum insulin secretion and insulin-glucose index were concerned, no differences of importance were observed between the injection group and the controls. Therefore, this study demonstrates that the effect of Injectio Mego-E on carbohydrate metabolism is of moderate degree and that transient post-injection hyperinsulinemia may have certain effect on carbohydrate homeostasis.     

THE EFFECT OF MONTHLY INJECTABLE CONTRACEPTIVE MEGESTROL ACETATE COMPOUND ON PITUITARY-OVARIAN FUNCTION

A study of injection megestrol acetate co. on the effect of pituitary-ovarian function was carried out in 4 healthy multiparous women. The serum levels of follicle stimularing hormone (FSH), luteinizing hormone (LH), prolactin (PRL), estradiol (E_2), progesterone (p) and cortisol (F) were assayed by RIA prior to treatment and at 1st, 6th and l2th treatment cycles. The hormonal profile before injection showed normal pituitary-ovarian function with ovulation-like change. During treatment the midcycle FSH-LH surges did not occur. The basal values of FSH at the beginning of each cycle were higher than those before treatment. 24h after injection E_2 increased and persisted at high level for about 5 days and then dropped down to low level The P levels were low throughout the whole cycle. PRL and F were in normal ranges. After treatment persistent high level of E_2 and "LH rebound action" could be seen. The above suggested that this injectable contraceptive has its effect of ovulation inhibition through suppression of midcycle peak of the gonadotrophic hormones. The follicular activity returned earlier than luteal activity. There were overian follicles developing in the ovaries. The rebound phenomenon of pituitary-ovarian function was present. The result of this study revealed that the effect of this injectable contraceptive on pitutaryovarian function is mild.     

米非司酮合并米索前列醇对113例停经50天以上妇女的抗早孕疗效观察

本文报告了1993年3月至8月用米非司酮合并米索前列醇终止停经50天以上早期妊娠113药物流产。从流产效果、引产时间、孕期与效果的关系、阴道出血情况、流产后月经恢复情况和尿hCG转阴时间等方面进行分析,结果发现,停经≥50天的孕妇使用药物流产完全流产率达91.4％,与文献报道对停经≤49天早孕妇女药物流产的疗效相仿;停经时间长短与产后阴道出血持续天数无明显关联;停经≥60天者不全流产率明显高于停经<60天的两组,且流产后尿hCG转阴时间较晚。因此认为药物流产可应用于停经50天以上的早孕,但对停经60天以上的孕妇应用药物流产要谨慎。     

上海市688对育龄夫妇连续使用Billings自然避孕法的临床效果观察及实验研究

本研究在1988,6～1990,5的两年间,对688对育龄夫妇进行了连续使用Billings 法的避孕效果与续用情况的观察,共10,275个妇女月;其中,550对夫妇连续使用12个月以上。用生命表统计分析,18个月和12个月时净累积停用率分别为34.58%和19.85%,续用率分别为65.42%和80.15%(因方法学意外妊娠分别为1.18%和1.02%,因方法学停用分别为2.84%和1.61%)。在观察临床效果的同时,对67例使用该法的志愿者进行阴道脱落细胞学检查,10例血、尿LH 和35例尿雌、孕激素测定。本文还对两年来临床观察和实验研究的多个方面进行了讨论,并认为该法值得进一步研究,可有组织、有计划地逐步扩大应用。     

米非司酮对子宫肌瘤组织中雌孕激素受体和表上生长因子受体的影响

目的：探讨米非司酮对子宫肌瘤组织内雌、孕激素受体和表皮生长因子受体的影响。方法：44例子宫肌瘤患者作全子宫切除或子宫肌瘤挖出术，其中米非司酮组16例，术前予米非司酮25mg，每日2次，连用3个月；对照组28例。采用免疫组化法测定子宫肌瘤及子宫平滑肌内雌、孕激素受体含量，用流式细胞仪测定EGFR水平。结果：米非司酮组子宫肌瘤及子宫平滑肌内PR较对照组显著下降（P＜0．01），ER无显著差异；米非司酮组子宫肌瘤及子宫平滑肌EGF－R水平显著低于对照组（P＜0．01）。结论：子宫肌瘤内EGF－R减少是米非司酮治疗后子宫肌瘤缩小的重要机制，这一作用可能与米非司酮阻断孕酮与PR的结合有关。     

促性腺激素释放激素激动剂对子宫肌瘤细胞凋亡调控基因Bcl-2/Bax mRNA表达的影响

目的　了解促性腺激素释放激素激动剂 (GnRHa)对子宫肌瘤细胞内凋亡调控基因Bcl- 2 /BaxmR NA表达的影响。方法　应用逆转录聚合酶链反应 (RT -PCR)法测定 12例经GnRHa治疗的子宫肌瘤内Bcl-2 /BaxmRNA水平 ,并以 2 1例未用药子宫肌瘤作对照。结果　GnRHa治疗者子宫肌瘤内Bcl- 2 /BaxmRNA比值较对照组显著下降 (P <0 0 1)。结论　子宫肌瘤内Bcl - 2 /BaxmRNA比值的下降继而诱导细胞凋亡可能是GnRHa治疗子宫肌瘤的分子机制之一。     

Application of Billings Method for Fertility Regulation

One hundred and thirteen women aged 25 to 47(totally 428 cycles) used Billings method for fertility regulation.Among them 76 women intended to postpone pregnancy or to adopt the natural method for contraception,the success rate of contraception was 92.59%(HWY).It is a safe,effective,simple and economic method and is more suitable for those new brides who want to postpone their pregnancies for a certain period of time,or for those couples who are contraindicated to use any kind of contraceptives of devices.     

米非司酮对子宫肌瘤组织中雌孕激素受体和表皮生长因子受体的影响

目的　探讨米非司酮对子宫肌瘤组织内雌、孕激素受体和表皮生长因子受体的影响。方法　 44例子宫肌瘤患者作全子宫切除或子宫肌瘤挖出术 ,其中米非司酮组 16例 ,术前予米非司酮 2 5mg ,每日 2次 ,连用 3个月 ;对照组 2 8例。采用免疫组化法测定子宫肌瘤及子宫平滑肌内雌、孕激素受体含量 ,用流式细胞仪测定EGF -R水平。结果　米非司酮组子宫肌瘤及子宫平滑肌内PR较对照组显著下降 (P <0 0 1) ,ER无显著差异 ;米非司酮组子宫肌瘤及子宫平滑肌EGF -R水平显著低于对照组 (P <0 0 1)。结论　子宫肌瘤内EGF -R减少是米非司酮治疗后子宫肌瘤缩小的重要机制 ,这一作用可能与米非司酮阻断孕酮与PR的结合有关。     

“美尔伊”避孕针的临床观察及实验研究

“美尔伊”避孕针系一个月注射一次的长效避孕针,临床试用1947例、20974个周期,避孕效果达99.43%。用药后月经周期正常者有87.17%,经期正常者86.80%,头昏、恶心等副反应极少见,突破性出血较多,占2%。停药后卵巢排卵功能恢复正常,一年内受孕率达76%。“美尔伊“避孕针主要通过抑制卵巢排卵而发挥作用,其次是子宫内膜和子宫颈粘液的改变,使之与卵巢周期变化不同步,从而影响受精或着床过程,达到避孕的目的。该针剂安全、有效、使用方便、成本低廉,有推广应用的价值。     

自身免疫性卵巢衰退小鼠动物模型的建立

临床上发现部分卵巢早衰者有自身免疫反应过强现象，外周血可测得抗卵巢抗体（ＡＯＡ）的存在。亦有报道病理检测部分闭经或月经不调患者之卵巢，发现有淋巴细胞浸润，诊断为自身免疫性卵巢炎。鉴于人体在体研究的限制性，故设计建立小鼠自身免疫性卵巢衰退动物模型，拟产生相似于人类疾病的病理及功能障碍，提供深入研究之手段。材料与方法一．小鼠卵巢抗原的制备及主动免疫（一）小鼠卵巢抗原的制备　取ＢＡＬＢ／ｃ小鼠（鼠龄３～６个月，体重３０克左右）卵巢组织，生理盐水漂洗去除血液成份后在少许ＴｒｉｓＨｃｌ缓冲液中将组织剪碎…